Source comparison
N-Adamantyl Semax: Full Comparison Table
Understanding how N-Adamantyl Semax compares to related nootropic peptides helps researchers select the most appropriate compound for their specific study design. The following table compares key pharmacological and practical characteristics: Half-Life 4–6 hou
This comparison does not assign a generated winner or score.
- Understanding how N-Adamantyl Semax compares to related nootropic peptides helps researchers select the most appropriate compound for their specific study design. The following table compares key pharmacological and practical characteristics:
- Half-Life
- 4–6 hours
- 70–90 minutes
- 2–3 hours
- Variable (protein mixture)
- N-Adamantyl Semax offers the longest duration among synthetic peptides in this class
- BBB Permeability
- High (lipophilic modification)
- Moderate
- Very High
- Moderate (requires IV)
- Lipophilic modifications significantly improve CNS penetration for research applications
- Primary Mechanism
- BDNF upregulation, neurotransmitter modulation
- BDNF upregulation
- HGF/Met pathway activation
- Multi-factor neurotrophic cocktail
- Each compound targets distinct but overlapping pathways relevant to neuroplasticity
- Administration Route
- Intranasal, subcutaneous
- Oral, subcutaneous
- Intravenous only
- Route flexibility is a practical advantage for diverse experimental protocols
- Preclinical Evidence Depth
- Moderate (10+ studies)
- Extensive (50+ studies)
- Growing (15+ studies)
- Extensive (clinical use in EU)
- Standard Semax has the largest preclinical dataset; N-Adamantyl Semax data is expanding
- Stability (reconstituted)
- 28 days at 2–8°C
- 21 days at 2–8°C
- 14 days at 2–8°C
- Single-use ampoule
- Extended stability reduces waste and supports longer experimental timelines